ReviewAnnals of cardiothoracic surgery2025
The current state of redo transcatheter aortic valve replacement (TAVR) and limitations: why TAVR explant is important as the valve reintervention strategy.
Review in Annals of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Minimally Invasive TAVR Explantation and Aortic Valve Replacement in a Patient With a Retrosternal Conduit.JACC. Case reports · 2026Article
- Navigating Complexity: Minimally Invasive TAVR Explantation in Patients With Retrosternal Conduits.JACC. Case reports · 2026Article
- Redo TAVR With Fluoroscopic-Free Surgical Resection of Prosthetic Valve Leaflets Under Direct Vision (SURPLUS) Technique.JACC. Asia · 2026Article
- Transcatheter Aortic Valve Implantation in Complex Anatomy: An Anatomy-Driven Framework for Bicuspid Stenosis, Pure Aortic Regurgitation, and the Small Annulus in the Era of Lifetime Management.Journal of clinical medicine · 2026Review
- TAVR Explant in the Era of Lifetime Valve Management: Indications, Operative Challenges, and Contemporary Outcomes.Current cardiology reports · 2026Review
- A decade of cardiac surgery after transcatheter aortic valve replacement: Short-term clinical outcomes at a high-volume center.JTCVS structural and endovascular · 2026Article
- Comparing short- and long-term outcomes of transcatheter valve-in-valve versus redo surgical aortic valve replacement: a literature review.Journal of cardiothoracic surgery · 2026Review
- Impact of surgical timing on outcomes after transcatheter aortic valve explantation: insights from a French multicenter retrospective study.Journal of cardiothoracic surgery · 2026Observational
- Lifetime Management of Aortic Stenosis: Evolving Strategies and Personalized Decision-Making.Journal of clinical medicine · 2026Review
- Surgical Explant of Degenerated Transcatheter Valves: A New Type of Threat?Interdisciplinary cardiovascular and thoracic surgery · 2026Review
- Fluid-structure interaction analysis of aortic valve dynamics: effects of aspect ratio.Regenerative biomaterials · 2026Article
- Transcatheter Aortic Valve Replacement for Aortic Insufficiency.Interventional cardiology (London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The rise of transcatheter aortic valve replacement (TAVR) over the past two decades has substantially changed the lifetime management of patients with aortic valve disease. As the indications for TAVR expand to include younger and lower-risk patients, the proportion of patients who subsequently require reintervention for failed transcatheter heart valves (THVs) will increase. The two primary options for reintervention are redo TAVR and TAVR explant followed by surgical aortic valve replacement (SAVR). The indications for redo TAVR in the short term include emergency "bailout" procedures due to malpositioning, embolization, or long-term device failure due to paravalvular leak (PVL) or valvular degeneration. However, redo TAVR is not suitable for all patients. Those with prohibitive coronary anatomy, multivalvular involvement, severe patient-prosthetic mismatch, or endocarditis should be referred for TAVR explant, which is a comparatively higher-risk procedure. Redo TAVR has generally been associated with low mortality and complication rates, with key procedural considerations being valve selection [e.g., sizing, balloon-expandable valve (BEV)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.